KNOA PHARMA Trademark

Trademark Overview


On Thursday, September 2, 2021, a trademark application was filed for KNOA PHARMA with the United States Patent and Trademark Office. The USPTO has given the KNOA PHARMA trademark a serial number of 97009389. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, June 25, 2024. This trademark is owned by Purdue Pharma L.P.. The KNOA PHARMA trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

A house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reve...

Pharmaceutical research and development
knoa pharma

General Information


Serial Number97009389
Word MarkKNOA PHARMA
Filing DateThursday, September 2, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, June 25, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 2, 2023

Trademark Statements


Goods and ServicesA house mark for a full line of pharmaceuticals; pharmaceuticals for use in the treatment of central nervous system disorders, pain, opioid overdose, opioid reversal, opioid use disorders, interstitial cystitis/bladder pain syndrome (IC/BPS), Overactive Bladder (OAB), Alcohol Use Disorder, Substance Use Disorder, sleep disorders including Insomnia Associated with Alcohol Cessation (IAAC), anaphylaxis; pharmaceuticals for use in the treatment of oncology conditions, specifically glioblastoma multiforme (GBM), non Hodgkin lymphoma, solid tumors, melanoma, chronic myelogenous leukemia, hemato-oncology, refractory/relapsed malignancies, alone or in combination with other agents; analgesics; pharmaceuticals, namely, opioid antagonists; syringes filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; syringes filled with opioid antagonists; injectors filled with pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectors filled with opioid antagonists; injectable pharmaceuticals for use in the treatment of opioid overdose, opioid reversal, or opioid use disorders; injectable pharmaceuticals, namely, opioid antagonists
NOT AVAILABLE"PHARMA"
Goods and ServicesPharmaceutical research and development

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, October 15, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NamePurdue Pharma L.P.
Party Type20 - Owner at Publication
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Party NamePurdue Pharma L.P.
Party Type10 - Original Applicant
Legal Entity Type13 - Limited Partnership
AddressStamford, CT 06901

Trademark Events


Event DateEvent Description
Monday, September 6, 2021NEW APPLICATION ENTERED
Friday, October 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, June 7, 2022ASSIGNED TO EXAMINER
Tuesday, June 14, 2022PRIORITY ACTION WRITTEN
Tuesday, June 14, 2022PRIORITY ACTION E-MAILED
Tuesday, June 14, 2022NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, December 6, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, December 7, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 15, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 27, 2022WITHDRAWN FROM PUB - OG REVIEW QUERY
Tuesday, March 7, 2023PREVIOUS ALLOWANCE COUNT WITHDRAWN
Thursday, March 16, 2023EXAMINERS AMENDMENT -WRITTEN
Thursday, March 16, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, March 16, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, March 16, 2023EXAMINER'S AMENDMENT ENTERED
Tuesday, May 2, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 2, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, March 27, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 27, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 19, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, December 19, 2023SOU EXTENSION 1 GRANTED
Tuesday, December 19, 2023SOU EXTENSION 1 FILED
Tuesday, June 25, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, June 25, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 25, 2024SOU EXTENSION 2 FILED
Tuesday, June 25, 2024SOU EXTENSION 2 GRANTED
Thursday, December 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED